Obinutuzumab May Be an Effective and Safe Option for Adult Minimal Change Disease and Focal Segmental Glomerulosclerosis Patients after Multitarget Therapy Including Rituximab
Obinutuzumab may be an efficient and safe option for inducing remission in adult MCD and FSGS patients who presented with nephrotic syndrome relapsing in short durations or failed to achieve remission after multitarget therapy, including rituximab. It was effective in maintaining remission in MCD patients, while its efficacy in maintaining remission in FSGS patients remained uncertain.
Authors
- Fei Han (ORCID: https://orcid.org/0000-0001-5363-7556)
- Yaomin Wang (ORCID: https://orcid.org/0009-0005-2182-7407)
- Yixuan Pan
- Pingping Ren (ORCID: https://orcid.org/0000-0002-4365-9222)
- Junni Wang
- Jianghua Chen (ORCID: https://orcid.org/0000-0002-3282-3998)
- Yuxin Lin (ORCID: https://orcid.org/0000-0001-9675-8083)
- Xin Lei (ORCID: https://orcid.org/0000-0003-1713-637X)
- Quan Han (ORCID: https://orcid.org/0000-0002-9869-9192)
- Jianhang Xu
- Liangliang Chen
- Lan Lan
Institutions
- National Clinical Research Center for Digestive Diseases (CN)
- Shanghai Clinical Research Center (CN)
- First Affiliated Hospital Zhejiang University (CN)
- Zhejiang University (CN)
Publication Details
- Journal
- American Journal of Nephrology
- Published
- 2024-10-11
- DOI
- https://doi.org/10.1159/000541972
- Citations
- 9
- Primary Topic
- Renal Diseases and Glomerulopathies
- Type
- article
- Field-Weighted Citation Impact
- 3.05